383 related articles for article (PubMed ID: 2116173)
41. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
Sirtori CR
Pharmacol Ther; 1993 Dec; 60(3):431-59. PubMed ID: 8073070
[TBL] [Abstract][Full Text] [Related]
42. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. 7. Modification of the hexahydronaphthalene moiety of simvastatin: 5-oxygenated and 5-oxa derivatives.
Duggan ME; Alberts AW; Bostedor R; Chao YS; Germershausen JI; Gilfillan JL; Halczenko W; Hartman GD; Hunt V; Imagire JS
J Med Chem; 1991 Aug; 34(8):2489-95. PubMed ID: 1875346
[TBL] [Abstract][Full Text] [Related]
43. Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells.
Hidaka Y; Hotta H; Nagata Y; Iwasawa Y; Horie M; Kamei T
J Biol Chem; 1991 Jul; 266(20):13171-7. PubMed ID: 1649182
[TBL] [Abstract][Full Text] [Related]
44. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
Alberts AW
Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
[TBL] [Abstract][Full Text] [Related]
45. Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis.
Hirano T; Komuro F; Furukawa S; Nagano S; Takahashi T
Metabolism; 1990 Jun; 39(6):605-9. PubMed ID: 2112675
[TBL] [Abstract][Full Text] [Related]
46. Effects of pravastatin sodium on mevalonate metabolism in common marmosets.
Miyazaki A; Koieyama T; Shimada Y; Kikuchi T; Nezu H; Ito K; Kasanuki N; Koga T
J Biochem; 2002 Sep; 132(3):395-400. PubMed ID: 12204108
[TBL] [Abstract][Full Text] [Related]
47. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors.
Newman A; Clutterbuck RD; Powles RL; Catovsky D; Millar JL
Leuk Lymphoma; 1997 Feb; 24(5-6):533-7. PubMed ID: 9086443
[TBL] [Abstract][Full Text] [Related]
48. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity.
Tesfamariam B; Frohlich BH; Gregg RE
J Cardiovasc Pharmacol; 1999 Jul; 34(1):95-101. PubMed ID: 10413074
[TBL] [Abstract][Full Text] [Related]
49. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.
Saheki A; Terasaki T; Tamai I; Tsuji A
Pharm Res; 1994 Feb; 11(2):305-11. PubMed ID: 8165193
[TBL] [Abstract][Full Text] [Related]
50. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?
Christians U; Jacobsen W; Floren LC
Pharmacol Ther; 1998 Oct; 80(1):1-34. PubMed ID: 9804052
[TBL] [Abstract][Full Text] [Related]
51. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
[TBL] [Abstract][Full Text] [Related]
52. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
Bergstrom JD; Bostedor RG; Rew DJ; Geissler WM; Wright SD; Chao YS
Biochim Biophys Acta; 1998 Jan; 1389(3):213-21. PubMed ID: 9512650
[TBL] [Abstract][Full Text] [Related]
53. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies.
Keidar S; Aviram M; Maor I; Oiknine J; Brook JG
Br J Clin Pharmacol; 1994 Dec; 38(6):513-9. PubMed ID: 7888289
[TBL] [Abstract][Full Text] [Related]
54. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
55. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
[TBL] [Abstract][Full Text] [Related]
56. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.
Morris MJ; Gilbert JD; Hsieh JY; Matuszewski BK; Ramjit HG; Bayne WF
Biol Mass Spectrom; 1993 Jan; 22(1):1-8. PubMed ID: 8431499
[TBL] [Abstract][Full Text] [Related]
57. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks.
Fears R; Richards DH; Ferres H
Atherosclerosis; 1980 Apr; 35(4):439-49. PubMed ID: 7189661
[TBL] [Abstract][Full Text] [Related]
58. [Hypercholesterolemia: therapeutic approach].
Alessandri C; Peverini F
Clin Ter; 1991 Jun; 137(6):373-97. PubMed ID: 1832610
[TBL] [Abstract][Full Text] [Related]
59. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
[TBL] [Abstract][Full Text] [Related]
60. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats.
Hooiveld GJ; Vos TA; Scheffer GL; Van Goor H; Koning H; Bloks V; Loot AE; Meijer DK; Jansen PL; Kuipers F; Müller M
Gastroenterology; 1999 Sep; 117(3):678-87. PubMed ID: 10464145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
